Back to Results

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Primary Objective

To evaluate the use of Enfortumab vedotin plus CPI in treatment of advanced bladder cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Thomas Flaig,  MD

Thomas Flaig, MD

Study ID

Protocol Number: 17-1410

More information available at ClinicalTrials.gov: NCT03288545

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers